Abstract:Basal cell carcinoma(BCC)is the most common type of skin cancer, with an increasing incidence in the eyelid each year, posing a significant health burden on patients. The Hedgehog(Hh)signaling pathway plays a crucial role in the occurrence and development of BCC, with its abnormal activation closely related to tumor formation. Therefore, Hh signaling pathway inhibitors have garnered increasing attention as an emerging therapeutic strategy. This article reviews the application of Hh signaling pathway inhibitors in the treatment of eyelid BCC, exploring their mechanisms of action, clinical effects, and future research directions. Through an analysis of existing literature, the potential of Hh signaling pathway inhibitors in treating BCC was summarized, the challenges faced in current clinical applications were highlighted, and pressing issues that need to be addressed were identified, aiming to provide references for future research and clinical practice.
